Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.
Detection of overall and index prostate cancer is comparable in three Tesla multiparametric magnetic resonance imaging (MRI) with and without an endorectal coil, a study has found. However, the endorectal coil subcohort has markedly higher detection of posterior and peripheral prostate cancer, as well as detection of anterior and transition zone prostate cancer.
A significant association exists between tumour volume-related parameters and radical prostatectomy, suggests a study. However, these parameters do not add important discriminatory value to standard clinicopathological variable for radical prostatectomy prediction or provide benefit across a range of clinically relevant decision thresholds.
Use of neither eicosapentaenoic acid (EPA) nor aspirin results in fewer patients with at least one colorectal adenoma, according to data from the Systematic Evaluation of Aspirin and Fish Oil Polyp Prevention trial.
The in-use stability of rituximab biosimilar Rixathon/Riximyo is not affected by dilution and formulation conditions needed for intravenous infusion even under worst case condition in terms of product shelf life, temperature excursion, light exposure, dilution factor and infusion bag storage time over a period of 31 days, according to biological and physicochemical analyses of a recent study.
Regular use of aspirin and direct oral anticoagulants (DOACs) appears to be associated with a lower positive predictive value of faecal immunochemical test (FIT) for detecting colorectal cancers and advanced adenomas, a study has found.
The severity, patterns over time and predictors of anxiety in children and adolescents undergoing chemotherapy or haematopoietic stem cell transplantation (HSCT) change with different instruments used, a new study has found.
Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.